R&D Insights: How Perrigo Company plc and Geron Corporation Allocate Funds

R&D Spending: A Tale of Two Companies

In the ever-evolving landscape of pharmaceuticals and biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Perrigo Company plc and Geron Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Perrigo consistently allocated a significant portion of its budget to R&D, peaking in 2018 with a 20% increase from the previous year. In contrast, Geron Corporation's R&D spending surged by over 500% from 2017 to 2023, reflecting a strategic pivot towards innovation. This divergence highlights Perrigo's steady commitment to incremental innovation, while Geron appears to be betting on breakthrough developments. As the industry faces new challenges and opportunities, these investment strategies will likely shape their competitive positions in the years to come.